VirTrack: A Framework for Inferring Viral Influence on Disease-Associated Transcriptomes — Clinical Type-Specific Epstein–Barr Virus Pathogenesis in Multiple Sclerosis
Preprint
Abstract
Background: Epstein–Barr virus (EBV) is strongly implicated in Multiple Sclerosis (MS), but how its influence varies across MS clinical types remains unclear. Methods: We developed VirTrack , a computational framework that integrates experimentally validated EBV–host protein–protein interactions (PPIs) with clinical type–specific peripheral blood transcriptomes from Clinically Isolated Syndrome (CIS), Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS) (GSE136411). VirTrack (i) anchors viral interactions in differentially expressed genes (DEGs), (ii) ranks EBV targeting of DEGs and host hubs, and (iii) applies machine learning– based clustering to identify clinical type–specific functional pathways influenced by EBV. Results: EBV engagement was clinical type–dependent. In early MS (CIS and RRMS), EBV targeted approximately 13–18% of dysregulated genes, enriching for B-cell–related processes, Toll-like receptor signaling, and infection-like inflammatory pathways, while suppressing antiviral and NF-κB responses. Progressive clinical types exhibited fewer viral connections but distinct mechanistic shifts: SPMS was characterized by suppression of vascular and cardiac repair–associated pathways, whereas PPMS was dominated by upregulation of vacuolar and lysosomal remodeling processes. Hub analyses revealed a stable core of influential EBV proteins, EBNA-LP (consistently top-ranked), BZLF1, BVLF1, LMP2, and BDLF4, while BNLF2A showed broad but less hub-focused targeting and LMP1 ranked low across types. Conclusion: EBV shapes MS through dynamic, clinical type–specific perturbations, driving strong immunomodulation in early disease and selective cellular remodeling during progressive types. VirTrack identifies key viral proteins and host pathways for stage-tailored therapeutic targeting, supporting early EBV-directed interventions and revealing potential links to vascular comorbidity in progressive MS types. More broadly, VirTrack offers a generalizable, systems-level framework for elucidating viral contributions across complex human diseases.Keywords
This publication has 58 references indexed in Scilit:
- Epstein-Barr virus reactivation is associated with altered immune cell profiles in peripheral blood and cerebrospinal fluid of treatment-naive multiple sclerosis patientsJournal of Neuroimmunology, 2025
- Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic ApproachCNS Drugs, 2025
- Anti-EBV: Artificial intelligence driven predictive modeling for repurposing drugs as potential antivirals against Epstein-Barr virusComputational and Structural Biotechnology Journal, 2025
- Insights into the interplay between Epstein‐Barr virus (EBV) and multiple sclerosis (MS): A state‐of‐the‐art review and implications for vaccine developmentHealth Science Reports, 2024
- Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in EnglandJAMA Neurology, 2020
- Virus-induced CD8 + T cells accelerate the onset of experimental autoimmune encephalomyelitis: Implications for how viral infections might trigger multiple sclerosis exacerbationsJournal of Neuroimmunology, 2013
- Increase in multiple sclerosis activity after assisted reproduction technologyAnnals of Neurology, 2012
- The Influence of Stress Factors on the Reactivation of Latent Herpes Simplex Virus Type 1 in Infected MiceCell Biochemistry and Biophysics, 2011
- Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological studyJournal of Neurology, 1993
- Stress-related activation of Epstein-Barr virusBrain, Behavior, and Immunity, 1991